BioMarin Pharmaceutical Inc. http://www.alacrastore.com/company-snapshot/BioMarin_Pharmaceutical_Inc-2100053 Sunday, November 23, 2008 4:21:01 AM 2100053 BioMarin Pharmaceutical Inc. en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/PRN-0005-29794442newstex/PRN-0005-29794442xml NOVATO, Calif., Nov. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dr. Emil Kakkis, its Chief Medical Officer will retire from the company on February ##, ####....11000000110090000400000004002000040020060401600004016013070000000701400007014012130000001301000013010005110060001100600811/21/2008 5:20:06 PM18000000180200001801500018007000PR Newswire USPRN-0005-29794442BIOMARIN PHARMACEUTICAL INCEMIL D KAKKISBMRNNewsNewstexhttp://www.alacrastore.com/storecontent/bir/952021bir/952021normBioMarin Pharmaceutical Inc.Glyko Biomedical LtdUnited StatesManufacturing: Enzyme therapies for debilitating, life-threatening, chronic genetic diseases and other diseases and conditions.283432541217EHBMRN10/31/2008 6:16:38 AM952021Company Profiles & FinancialsGale Company Profileshttp://www.alacrastore.com/storecontent/ccbn/B1975323ccbn/B1975323norm...Does not expect any of three commercial products will face any direct competition for foreseeable future. ... 10/28/2008 11:06:00 PMBioMarin Pharmaceutical Inc.54.0000EditedBioMarin Pharmaceutical Inc. Q3 2008 Earnings Conference Call SummaryBMRN5:00pm ETBriefB1975323Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1975323ccbn/T1975323norm...Good day, ladies and gentlemen and welcome to the third-quarter #### BioMarin Pharmaceuticals Inc. earnings conference call. My name is Stacy and I will be your conference moderator for today. At this time all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of the conference. (OPERATOR INSTRUCTIONS). As a reminder, this conference is being recorded for replay purposes. I would now like to turn the presentation over to your host for today's call, as Ms. Eugenia Shen, Senior Manager of Investor Relations. ... 10/28/2008 8:06:00 PMBioMarin Pharmaceutical Inc.54.0000FinalBioMarin Pharmaceutical Inc. Q3 2008 Earnings Conference Call TranscriptBMRN5:00pm ETTranscriptT1975323Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1997867ccbn/T1997867norm...Good day, ladies and gentlemen, and welcome to the BioMarin Pharmaceutical Results from Phase #a Study of #R-BH# in Sickle Cell Disease Conference Call. My name is Krista, and I will be your operator for today. At this time, all participants are in listen-only mode. We will conduct a question and answer session towards the end of this conference. (OPERATOR INSTRUCTIONS.) As a reminder, this conference is being recorded for replay purposes. I would now like to turn the call over to Ms. Eugenia Shen, Senior Manager of Investor Relations. Please proceed, ma'am. ... 10/16/2008 11:08:00 AMBioMarin Pharmaceutical Inc.54.0000FinalBioMarin Pharmaceutical Phase 2a Results of 6R-BH4 in Sickle Cell Disease Conference Call TranscriptBMRN2:00pm PTTranscriptT1997867Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B1997867ccbn/B1997867norm...Co. announced positive results from Phase #a Sickle Disease study, which demonstrates that administration of #R-BH# resulted in a sophistically significant improvement in endothelial dysfunction. ... 10/15/2008 9:06:00 PMBioMarin Pharmaceutical Inc.54.0000EditedBioMarin Pharmaceutical Phase 2a Results of 6R-BH4 in Sickle Cell Disease Conference Call SummaryBMRN2:00pm PTBriefB1997867Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/PRN-0005-28586909newstex/PRN-0005-28586909xml NOVATO, Calif., Oct. #, #### (PRNewswire-FirstCall delivered by Newstex) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and...0400000004002000040020060401600004016048040160180401601307000000070140000701401213000000130100001301000510/7/2008 10:24:05 AM1800000018004000180080001801500018020000PR Newswire USPRN-0005-28586909BIOMARIN PHARMACEUTICAL INCBMRNNewsNewstexhttp://www.alacrastore.com/storecontent/spcred/669980spcred/669980normThe latest Full Report from S&Pglobal9/8/2008 1:03:56 PM400Full Report669980United StatesBiotechnologyUnited StatesGlobal IssuersCorporationsConsumer ProductsHealth CareFull ReportPortfolio of three significant, fast growing products-–Aldurazyme, Naglazyme, and Kuvan; and More than adequate liquidity to fund research and development (R&D) and operations. No track record of positive earnings and expected negative free cash flows in intermediate term. The speculative-grade rating on BioMarin Pharmaceutical Inc. reflects the company's expected continued operating losses and cash outflows in the intermediate term, primarily because of increasing R&D expenditures and marketing costs, and still narrow product portfolio. These factors are offset partially by BioMarin's improving operating performance and adequate liquidity. Novato, Calif.-based BioMarin specializes in the development and commercialization of drugs that treat serious enzyme deficiency-related diseases. The company has three main products--Aldurazyme, an enzyme replacement therapy for the treatment of the genetic diseaseUSA09061G35201010 352010 3520 35BioMarin Pharmaceutical Inc.400480USABMRNFULLGLOBISSCORPConsumerHealthCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/spcred/669983spcred/669983normThe latest Research Update from S&Pglobal9/8/2008 1:03:56 PM175Research Update669983United StatesBiotechnologyUnited StatesGlobal IssuersCorporationsHealth CareConsumer ProductsResearch UpdateOn June 24, 2008, Standard&Poor's Ratings Services revised its outlook on Novato, Calif.-based BioMarin Pharmaceutical Inc. to positive from stable, and affirmed its 'B-' corporate credit and 'CCC' subordinated debt ratings on the company. The outlook revision reflects BioMarin's improving financial performance, based on strong sales growth of its three key products. Our speculative-grade rating on BioMarin Pharmaceutical Inc. reflects the company's expected cash outflows in the intermediate term, primarily because of increasing research and development expenditures and marketing costs, and still narrow product portfolio. These factors partly are offset by BioMarin's improving operating performance and adequate liquidity. BioMarin specializes in the development and commercialization of drugs that treat serious enzyme deficiency-related diseases. The company has three mainUSA09061G35201010 352010 3520 35BioMarin Pharmaceutical Inc.400480USABMRNRESUPDGLOBISSCORPHealthConsumerCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/spcred/669981spcred/669981normThe latest Summary from S&Pglobal9/8/2008 1:03:00 PM175Summary669981United StatesBiotechnologyUnited StatesGlobal IssuersCorporationsHealth CareConsumer ProductsSummaryThe speculative-grade rating on BioMarin Pharmaceutical Inc. reflects the company's expected continued operating losses and cash outflows in the intermediate term, primarily because of increasing research and development expenditures and marketing costs, and still narrow product portfolio. These factors are offset partially by BioMarin's improving operating performance and adequate liquidity. Novato, Calif.-based BioMarin specializes in the development and commercialization of drugs that treat serious enzyme deficiency-related diseases. The company has three main products--Aldurazyme, an enzyme replacement therapy for the treatment of the genetic disease mucopolysaccharidosis I (MPS I); Naglazyme, a drug for the treatment of MPS VI; and the recently launched Kuvan, a small molecule treatment for phenylketonuria, an inherited metabolic disease. All three products address niche disease markets, enjoyUSA09061G35201010 352010 3520 35BioMarin Pharmaceutical Inc.400480USABMRNSUMMARYGLOBISSCORPHealthConsumerCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/ccbn/T1931667ccbn/T1931667norm...Good day, ladies and gentlemen, and welcome to the National PKU Registry Roll-Out and Company Update Conference Call. My name is Chanel and I will be your coordinator for today. (Operator Instructions) As a reminder, this conference is being recorded for replay purposes. I would now like to turn the presentation over to your host for today's conference, Ms. Eugenia Shen. Please proceed. ... 8/22/2008 12:08:00 AMBioMarin Pharmaceutical Inc.54.0000FinalBioMarin Pharmaceutical Inc.: National PKU Registry Roll-Out and Company Update Conference Call TranscriptBMRN1:30pm PTTranscriptT1931667Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B1931667ccbn/B1931667norm...Last summer, Naglazyme sales in #Q of the year were basically flat vs. #Q of the year at around $##m. ... 8/21/2008 9:06:00 PMBioMarin Pharmaceutical Inc.54.0000EditedBioMarin Pharmaceutical Inc.: National PKU Registry Roll-Out and Company Update Conference Call SummaryBMRN1:30pm PTBriefB1931667Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B1790732ccbn/B1790732norm...Naglazyme, Aldurazyme, and Kuvan are generating strong top line revenues which increased profitability for the third consecutive qtr. ... 8/5/2008 10:07:00 PMBioMarin Pharmaceutical Inc.106.0000EditedBioMarin Pharmaceutical Inc. Q2 2008 Earnings Conference Call SummaryBMRN2:00pm PTBriefB1790732Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1790732ccbn/T1790732norm...Good day, ladies and gentlemen, and welcome to the second quarter #### BioMarin Pharmaceutical, Inc. earnings conference call. I will be your coordinator for today. At this time all participants are in a listen-only mode. We'll facilitate a question-and-answer session towards the end of today's conference. (OPERATOR INSTRUCTIONS) ... 8/5/2008 7:05:00 PMBioMarin Pharmaceutical Inc.106.0000FinalBioMarin Pharmaceutical Inc. Q2 2008 Earnings Conference Call TranscriptBMRN2:00pm PTTranscriptT1790732Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1889117ccbn/T1889117norm...I'm pleased to have BioMarin presenting this morning and presenting from the Company is the Chief Medical Officer, Emil Kakkis.... 7/15/2008 4:04:00 PMBioMarin Pharmaceutical Inc.54.0000FinalBioMarin Pharmaceutical Inc. at Collins Stewart 4th Annual Growth Conference TranscriptBMRN9:30am ETTranscriptT1889117Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/spcred/655918spcred/655918normThe latest News from S&Pglobal6/24/2008 6:28:25 PM100News655918United StatesBiotechnologyUnited StatesGlobal IssuersCorporationsConsumer ProductsHealth CareNewsNEW YORK (Standard&Poor's) June 24, 2008--Standard&Poor's Ratings Services said today that it revised its outlook on Novato, Calif.-based BioMarin Pharmaceutical Inc. to positive from stable, and affirmed its 'B-' corporate credit and 'CCC' subordinated debt ratings on the company. "The outlook revision reflects BioMarin's improving financial performance, based on strong sales growth of its three key products," said Standard&Poor's credit analyst Arthur Wong. Our speculative-grade rating on BioMarin Pharmaceutical Inc. reflects the company's expected cash outflows in the intermediate term, primarily because of increasing research and development expenditures and marketing costs, and still narrow product portfolio. These factors partly are offset by BioMarin's improving operating performance and adequate liquidity. BioMarin specializes in the developmentUSA09061G35201010 352010 3520 35BioMarin Pharmaceutical Inc.400480USABMRNNEWSGLOBISSCORPConsumerHealthCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/spcred/655919spcred/655919normThe latest Research Update from S&Pglobal6/24/2008 6:28:25 PM175Research Update655919United StatesBiotechnologyUnited StatesGlobal IssuersCorporationsConsumer ProductsHealth CareResearch UpdateOn June 24, 2008, Standard&Poor's Ratings Services revised its outlook on Novato, Calif.-based BioMarin Pharmaceutical Inc. to positive from stable, and affirmed its 'B-' corporate credit and 'CCC' subordinated debt ratings on the company. The outlook revision reflects BioMarin's improving financial performance, based on strong sales growth of its three key products. Our speculative-grade rating on BioMarin Pharmaceutical Inc. reflects the company's expected cash outflows in the intermediate term, primarily because of increasing research and development expenditures and marketing costs, and still narrow product portfolio. These factors partly are offset by BioMarin's improving operating performance and adequate liquidity. BioMarin specializes in the development and commercialization of drugs that treat serious enzyme deficiency-related diseases. The company has three mainUSA09061G35201010 352010 3520 35BioMarin Pharmaceutical Inc.400480USABMRNRESUPDGLOBISSCORPConsumerHealthCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/ccbn/T1783887ccbn/T1783887norm...Good day, ladies and gentlemen, and welcome to the first quarter BioMarin Pharmaceutical earnings conference call. My name is Katie and I'll be your coordinator for today. At this time all participants will be in a listen-only mode. We will be facilitating a question and answer session towards the end of this conference. (OPERATOR INSTRUCTIONS) ... 4/30/2008 2:06:00 AMBioMarin Pharmaceutical Inc.54.0000FinalQ1 2008 BioMarin Pharmaceutical Inc. Earnings Conference Call TranscriptBMRN5:00pm ETTranscriptT1783887Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B1783887ccbn/B1783887norm...Naglazyme, Aldurazyme, and launch of Kuvan generated strong topline revenue, with strong profitability. ... 4/29/2008 10:06:00 PMBioMarin Pharmaceutical Inc.54.0000EditedQ1 2008 BioMarin Pharmaceutical Inc. Earnings Conference Call SummaryBMRN5:00pm ETBriefB1783887Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/spcred/644218spcred/644218normThe latest Summary from S&Pglobal4/22/2008 6:19:56 PM175Summary644218United StatesBiotechnologyUnited StatesGlobal IssuersCorporationsConsumer ProductsHealth CareSummaryThe speculative-grade rating on BioMarin Pharmaceutical Inc. reflects the company's expected continued operating losses and cash outflows in the intermediate term, primarily because of increasing research and development expenditures and marketing costs, and still narrow product portfolio. These factors are offset partially by BioMarin's improving operating performance and adequate liquidity. Novato, Calif.-based BioMarin specializes in the development and commercialization of drugs that treat serious enzyme deficiency-related diseases. The company has three main products--Aldurazyme, an enzyme replacement therapy for the treatment of the genetic disease mucopolysaccharidosis I (MPS I); Naglazyme, a drug for the treatment of MPS VI; and the recently launched Kuvan, a small molecule treatment for phenylketonuria, an inherited metabolic disease. All three products address niche disease markets, enjoyUSA09061G35201010 352010 3520 35BioMarin Pharmaceutical Inc.400480USABMRNSUMMARYGLOBISSCORPConsumerHealthCredit & Investment ResearchS&P Credit Research